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The CoLaus study is a large population based cross sec-
tional study in over 6000 subjects aged 35-75 years living
in Lausanne, Switzerland. Its main goals are to obtain
information on (1) The prevalence of cardiovascular risk
factors and diseases in the population of Lausanne,
(2) New biologic and genetic determinants of isolated and
clusters of cardiovascular risk factors.
Recruitment was done from 2003 to 2006 to obtain a
representative sample of subjects. The participation rate
was 42%. The participants were extensively phenotyped by
administering a questionnaire on personal and family his-
tory of cardiovascular risk factors & personal medical his-
tory, a basic physical exam for cardiovascular risk factors,
mental status examination and biological markers in blood
and urine. Plasma, serum, whole blood and urine were
stored at -80oC and all Caucasian subjects were genotyped
with database in Lausanne.
Starting in 2004, over 3600 CoLaus participants under-
went an extensive psychiatric phenotypization (PsyCo-
Laus). This extensive phenotype should allow us to better
understand the known association between cardiovascular
diseases and mental health.
In May 2009 follow-up of the entire CoLaus population
was started to prospectively assess the association between
cardiovascular diseases, cardiovascular risk factors and
mental disorders. Data were collected to know the course
of the conditions related to cardiovascular diseases or
mental disorders observed at baseline, the incidence of
such conditions during the follow-up and the evaluation
of candidate variables which could be either mediators of
a causal relationship or shared factors underlying the asso-
ciation between mental disorders and cardiovascular
diseases.
Several sub-studies were also started like:
(1) AngioLaus – a case control study in which 500 par-
ticipants underwent detailed cardiovascular pheno-typing
including intima-media thickness in the carotid arteries,
pulse-wave velocity, central arterial pressure and
endothelial function before and during reactive
hyperaemia.
(2) HERCULES - to study the prevalence of hyperten-
sion using 24-hour ambulatory blood pressure measure-
ment, to assess renal function using 24-hour urine
collection (creatinine clearance, micro-albuminuria) and
to expand understanding of genetic variants associated
with hypertension and renal function within the CoLaus
study.
(3) OsteoLaus - to compare risk models to discrimi-
nate osteoporotic fractures, to better understand the
association of osteoporosis, cardiovascular diseases &
mental health and to determine the genetic determi-
nants of osteoporosis.
(4) HypnoLaus - to determine the prevalence of sleep
disorders in the general population, to assess the genetic
basis of sleep and its disorders and for better characteri-
zation of a potential link between cardiovascular disease
risk factors and mental health.
Each subject had reversible anonymised unique identifi-
cation barcode and samples in the bio-bank were identi-
fied with barcodes. The data are stored in an Oracle
database updated with Epi-data software. A scientific advi-
sory board consisting of external scientists evaluate the
progression of the project. The participant motivation is
being sustained with regular newsletters and interactive
website. The project had received funding from GlaxoS-
mithKline initially and is currently supported by the Swiss
National Science Foundation. There have been over 100
publications with more than 3000 citations so far from the
project.
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